Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals.
The previously unknown coronavirus that caused severe acute respiratory syndrome (SARS-CoV) affected more than 8,000 persons worldwide and was responsible for more than 700 deaths during the first outbreak in 2002-2003. For reasons unknown, the SARS virus is less severe and the clinical progression a great deal milder in children younger than 12 years of age. In contrast, the mortality rate can exceed 50% for persons at or above the age of 60. As part of the Sino-European Project on SARS Diagnostics and Antivirals (SEPSDA), an immune phage-display library is being created from convalescent patients in a phagemid system for the selection of single-chain fragment variables (scFv) antibodies recognizing the SARS-CoV.
Sørensen
Morten Draeby
MD
Department of Molecular Biology, University of Aarhus, Denmark.
Sørensen
Brian
B
Gonzalez-Dosal
Regina
R
Melchjorsen
Connie Jenning
CJ
Weibel
Jens
J
Wang
Jing
J
Jun
Chen Wie
CW
Huanming
Yang
Y
Kristensen
Peter
P
D000914:Antibodies, Viral / Q000276:immunology*; D000998:Antiviral Agents / Q000276:immunology / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007128:Immunoglobulin Fragments / Q000276:immunology; D019151:Peptide Library; D045473:Severe acute respiratory syndrome-related coronavirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D012699:Serology; D045169:Severe Acute Respiratory Syndrome / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy* / Q000821:virology
D000914:Antibodies, Viral; D000998:Antiviral Agents; D007128:Immunoglobulin Fragments; D019151:Peptide Library